Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01584440 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
A Phase 2 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT01584440 is a Phase 2 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 220 participants.
The verdict
NCT01584440, a Phase 2 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
Interventions
- DRUG Placebo
- DRUG AVP-923-30
- DRUG AVP-923-20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-08-13 |
| Est. Completion | 2014-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01584440
The ClinicalTrials.gov registry entry for NCT01584440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01584440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01584440 about?
NCT01584440 is a clinical study titled "Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease". The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
What is the current status of trial NCT01584440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2012-08-13. Estimated completion is 2014-07-30.
What interventions are being tested in trial NCT01584440?
The interventions under investigation include: Placebo (DRUG), AVP-923-30 (DRUG), AVP-923-20 (DRUG).
Who is sponsoring clinical trial NCT01584440?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.